Carly Newton: Closing the Gap in Sickle Cell Disease Readmissions
Carly Newton, Sr Manager of Apheresis Clinical Marketing at Terumo Blood and Cell Technologies, shared a post on LinkedIn:
“1 in 3 adults with sickle cell disease are back in the hospital within 30 days of discharge. For some young adults, it’s closer to 40%.
Behind every one of those readmissions is another crisis, more missed work or school, more strain on a family.
The data is consistent: transfusion therapy, especially automated red blood cell exchange (aRBCX), lowers that risk, even for the sickest patients. Yet fewer than 3% of SCD patients access RBCX each year, despite most having the access and prescriber support to get it.
This September, for National Sickle Cell Awareness Month, I’m breaking down why that gap exists and what closing it could mean for the people living this every day.
Read the full article on my Substack.”
Stay updated withΒ Hemostasis Today.
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events
-
Nov 8, 2026, 14:05Kausik Ray: Plaque-Guided Care for Better Coronary Outcomes
-
Nov 8, 2026, 14:05Athira Elssa Johnson: Understanding Coronary Thrombosis and Its Risks
-
Nov 8, 2026, 14:04Sanjiv Beri: Blood Type Compatibility and the Balance of Giving and Receiving
-
Nov 8, 2026, 14:02Gabriela Hobbs: Recognizing Outstanding Abstract Achievements-ASH 2026